Sequencing of hormonal therapy in breast cancer

Breast Journal

Volumn 8, Issue 6, 2002, Pages 332-337

  Ingle, James N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adjuvant; Breast cancer; Hormonal therapy; Metastatic; Sequencing

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ARIMEDEX; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOXORUBICIN; ESTROGEN; EXEMESTANE; FADROZOLE; FLUOROURACIL; FULVESTRANT; GONADORELIN; GOSERELIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHOTREXATE; TAMOXIFEN; TESTOLOLACTONE; VOROZOLE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; OVARIECTOMY; POSTMENOPAUSE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PREMENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, LHRH; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0036848928     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2002.08602.x     Document Type: Article

References (37)

1. Ingle JN. Current status of adjuvant endocrine therapy for breast cancer. Clin Cancer Res 2001;7:S4392-96.
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-67.
3. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90.
4. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19:881-94.
5. Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women. Breast Cancer Res Treat 2001;69:210.
6. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor positive breast cancer: status report 2002. J Clin Oncol 2002;20:3317-27.
7. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606.
8. Mouridsen H, Sun Y, Gershanovich M, et al. Final survival analysis of the double-blind, randomized multinational phase III trial of letrozole (Femara®) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer. Breast Cancer Res Treat 2001;69:211.
9. Nabholtz JM, Buzdar A, Pollack M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women - Results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758-76.
10. Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women - Results of the TARGET (Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability) Study. J Clin Oncol 2000;18: 3748-57.
11. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92: 2247-58.
12. Paridaens R, Dirix LY, Beex L, et al. Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (Pts): Results of a randomized phase II trial [abstract 316]. Proc Am Soc Clin Oncol 2000;19:83a.
13. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998;83:1142-52.
14. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;6:453-61.
15. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-411.
16. Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) vs. anastrozole (Arimidex): Second-line treatment in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:34a.
17. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 2000;18:2234-44.
18. Bertelli G, Garrone O, Merlano M. Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:60a.
19. Osborne CK. A double-blind randomized trial comparing the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat 2000;64:27.
20. Howell A, Robertson JFR, Quaresma AJ, et al. Comparison for efficacy and tolerability of fulvestrant (Faslodex) with anastrozole (Arimidex) in postmenopausal women with advanced breast cancer (ABC). Breast Cancer Res Treat 2000;64:27.
21. Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res 2002;4:133-6.
22. Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111-6.
23. Crump M, Sawka CA, DeBoer G, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 1997;44:201-10.
24. Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in pre-menopausal patients with receptor positive metastatic breast cancer: An intergroup study. J Clin Oncol 1998;16:994-9.
25. Klijn JG, Beex LVAM, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000;92:903-11.
26. Klijn JGM, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53.
27. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348:1189-96.
28. Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000;18:2718-27.
29. Jakesz R, Hausmaninger H, Samonigg H, et al. Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5 [abstract 250]. Proc Am Soc Clin Oncol 1999;18:67a.
30. Jakesz R, Gnant M, Hausmaninger H, et al. Combination goserelin and tamoxifen is more effective than CMF in premenopausal patients with hormone-responsive tumors in a multicenter trial of the Austrian Breast Cancer Study Group (ABCSG). Breast Cancer Res Treat 1999;57:25.
31. Roche H, de Mihura J, Lafontan B, et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptor positive breast cancer patients: A randomized trial with a 7 year median follow up [abstract 134]. Proc Am Soc Clin Oncol 1996;15:117.
32. Roche HH, Kerbrat P, Bonneterre J, et al. Complete hormonal, blockade versus chemotherapy in premenopausal early-stage breast cancer patients (Pts) with positive hormone-receptor (HT+) and 1-3 node-positive (N+) tumor: Results of the FASG 06 trial [abstract 279]. Proc Am Soc Clin Oncol 2000;19:72a.
33. Davidson N, O'Neill A, Vukov A, et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, Int-0101) [abstract 249]. Proc Am Soc Clin Oncol 1999;18:67a.
34. Pagani O, O'Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) trial IV. Eur J Cancer 1998;34:632-40.
35. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29.
36. Stone ER, Slack RS, Novielli A, et al. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant Adriamycin and Cytoxan (AC) and Adriamycin and Cytoxan followed by Taxol (AC+T) in early stage breast cancer. Breast Cancer Res Treat 2000;64:61.
37. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355:1869-74.